Using engineered T cells to treat glioblastoma
Engineering T Cell Adoptive Therapy for Glioblastoma
This study is exploring a new treatment for glioblastoma, a tough type of brain cancer, by using specially engineered immune cells to help the body fight the tumor better, with hopes of making this therapy available for patients in the future.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11091578 on NIH RePORTER |
What this research studies
This research investigates the use of T cell receptor (TCR) directed therapy in treating glioblastoma, a challenging brain cancer with poor outcomes. The approach involves the adoptive transfer of engineered T cells to enhance the immune response against the tumor. Researchers will study preclinical models to understand how these T cells can effectively target glioblastoma cells, overcoming the unique challenges posed by the brain's immune environment. The ultimate goal is to pave the way for future clinical applications of this therapy in patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with glioblastoma who are 21 years or older.
Not a fit: Patients with other types of brain tumors or those under 21 years old may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new immunotherapy options for glioblastoma patients, potentially improving treatment outcomes.
How similar studies have performed: While immunotherapy has shown success in other cancers, this specific approach for glioblastoma is novel and has not yet been tested in clinical settings.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Dunn, Gavin Peter — Massachusetts General Hospital
- Study coordinator: Dunn, Gavin Peter
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.